Remifentanil, a short-acting potent μ-opioid agonist proposed for intraoperative analgesia
but also for postoperative pain therapy, has not been investigated with regard to the effects …

Background and aim: Remifentanil is an ultra‐short‐acting opioid, increasingly used today
in neuroanesthesia and neurointensive care. Its characteristics make remifentanil a …

Remifentanil hydrochloride is an ultra-short-acting esterase metabolized mu-opioid receptor
agonist. The purpose of this study was to provide preliminary information regarding the …

Background: Remifentanil, an ultra‐short‐acting opioid, is used as an on‐top analgesic in
head trauma patients during transient painful procedures, eg endotracheal suctioning …

We have used contrast media‐enhanced perfusion magnetic resonance imaging MRI to
measure regional cerebral blood flow (rCBF), regional cerebral blood volume (rCBV) …

OBJECTIVE: Remifentanil is a selective μ-opioid agonist with a context-sensitive half-time of
3 to 5 minutes, independent of dose or administration duration. Other desirable effects …

When a new drug is introduced into neuroanesthesia practice, several considerations must
be addressed. A principal concern is drug effect on cerebral perfusion pressure (CPP) …

In the present study, we investigated the effect of remifentanil on cerebral blood flow velocity
(CBFV). We investigated 20 patients (ASA physical status III) scheduled for elective coronary …

Remifentanil is increasingly used in the context of anesthesia, eg, in patients presenting for
MRI examinations, not only as an analgesic but also to replace nitrous oxide. Therefore, a …

Background The current study investigated dose-dependent effects of the mu-selective
agonist remifentanil on regional cerebral blood flow (rCBF) in volunteers using positron …